Tetrac can replace thyroid hormone during brain development in mouse mutants deficient in the thyroid hormone transporter Mct8

Endocrinology

Volumn 154, Issue 2, 2013, Pages 968-979

  Horn, Sigrun ^a   Kersseboom, Simone ^b   Mayerl, Steffen ^a   Müller, Julia ^a   Groba, Claudia ^a   Trajkovic Arsic, Marija ^a,c   Ackermann, Tobias ^a   Visser, Theo J ^b   Heuer, Heike ^a  

^a FRITZ LIPMANN INSTITUTE   (Germany)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IODIDE PEROXIDASE; LIOTHYRONINE; MONOCARBOXYLATE TRANSPORTER 8; TETRACAINE; THYROID HORMONE; THYROID HORMONE RECEPTOR; TIRATRICOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN DEVELOPMENT; CELL LINE; CELL MATURATION; CEREBELLUM; CLINICAL EVALUATION; CONGENITAL HYPOTHYROIDISM; CONTROLLED STUDY; CORPUS STRIATUM; GENE INACTIVATION; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HORMONE TRANSPORT; IN VIVO STUDY; MALE; MOUSE; NERVE CELL; NERVE CELL DIFFERENTIATION; NERVE CELL LESION; NEWBORN; NONHUMAN; PERINATAL PERIOD; PRIORITY JOURNAL; PURKINJE CELL;

ANIMALS; BRAIN; CERCOPITHECUS AETHIOPS; COS CELLS; MEMBRANE TRANSPORT PROTEINS; MICE; MICE, KNOCKOUT; THYROXINE;

EID: 84872708609     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2012-1628     Document Type: Article

References (59)

1. Dumitrescu AM, Liao XH, Best TB, Brockmann K, Refetoff S. A novel syndrome combining thyroid and neurological abnormalities is associated with mutations in a monocarboxylate transporter gene. Am J Hum Genet. 2004;74:168-175. (Pubitemid 38085248)
2. Friesema EC, Grueters A, Biebermann H, et al. Association between mutations in a thyroid hormone transporter and severe X-linked psychomotor retardation. Lancet. 2004;364:1435-1437. (Pubitemid 39370719)
3. Schwartz CE, May MM, Carpenter NJ, et al. Allan-Herndon-Dudley syndrome and the monocarboxylate transporter 8 (MCT8) gene. Am J Hum Genet. 2005;77:41-53. (Pubitemid 40848035)
4. 3 levels caused by mutations in monocarboxylate transporter 8. Nat Clin Pract Endocrinol Metab. 2006;2:512-523.
5. Refetoff S, Dumitrescu AM. Syndromes of reduced sensitivity to thyroid hormone: genetic defects in hormone receptors, cell transporters and deiodination. Best Pract Res Clin Endocrinol Metab. 2007;21:277-305. (Pubitemid 46888195)
6. Friesema EC, Visser WE, Visser TJ. Genetics and phenomics of thyroid hormone transport by MCT8. Mol Cell Endocrinol. 2010;322:107-113.
7. Oppenheimer JH, Schwartz HL. Molecular basis of thyroid hormone-dependent brain development. Endocr Rev. 1997;18:462-475. (Pubitemid 27349552)
8. de Escobar GM, Obregon MJ, del Rey FE. Maternal thyroid hormones early in pregnancy and fetal brain development. Best Pract Res Clin Endocrinol Metab. 2004;18:225-248.
9. Bernal J. Thyroid hormones and brain development. Vitam Horm. 2005;71:95-122. (Pubitemid 43589035)
10. Wemeau JL, Pigeyre M, Proust-Lemoine E, et al. Beneficial effects of propylthiouracil plus L-thyroxine treatment in a patient with a mutation in MCT8. J Clin Endocrinol Metab. 2008;93:2084-2088. (Pubitemid 351831519)
11. Dumitrescu AM, Liao XH, Weiss RE, Millen K, Refetoff S. Tissue-specific thyroid hormone deprivation and excess in monocarboxylate transporter (MCT) 8-deficient mice. Endocrinology. 2006;147:4036-4043. (Pubitemid 44268357)
12. Trajkovic M, Visser TJ, Mittag J, et al. Abnormal thyroid hormone metabolism in mice lacking the monocarboxylate transporter 8. J Clin Invest. 2007;117:627-635. (Pubitemid 46348521)
13. Ceballos A, Belinchon MM, Sanchez-Mendoza E, et al. Importance of monocarboxylate transporter 8 for the blood-brain barrier-dependent availability of 3,5,3′-triiodo-L-thyronine. Endocrinology. 2009;150:2491-2496.
14. 3 transporter mutated in Allan-Herndon-Dudley syndrome. J Neurosci. 2009;29:9439-9449.
15. Sugiyama D, Kusuhara H, Taniguchi H, et al. Functional characterization of rat brain-specific organic anion transporter (Oatp14) at the blood-brain barrier: high affinity transporter for thyroxine. J Biol Chem. 2003;278:43489-43495. (Pubitemid 37345972)
16. Tohyama K, Kusuhara H, Sugiyama Y. Involvement of multispecific organic anion transporter, Oatp14 (Slc21a14), in the transport of thyroxine across the blood-brain barrier. Endocrinology. 2004;145:4384-4391. (Pubitemid 39120588)
17. Roberts LM, Woodford K, Zhou M, et al. Expression of the thyroid hormone transporters monocarboxylate transporter-8 (SLC16A2) and organic ion transporter-14 (SLCO1C1) at the blood-brain barrier. Endocrinology. 2008;149:6251-6261.
18. Ito K, Uchida Y, Ohtsuki S, et al. Quantitative membrane protein expression at the blood-brain barrier of adult and younger cynomolgus monkeys. J Pharm Sci. 2011;100:3939-3950.
19. Mayerl S, Visser TJ, Darras VM, Horn S, Heuer H. Impact of oatp1c1 deficiency on thyroid hormone metabolism and action in the mouse brain. Endocrinology. 2012;153:1528-1537.
20. Di Cosmo C, Liao XH, Dumitrescu AM, Weiss RE, Refetoff S. A thyroid hormone analog with reduced dependence on the monocarboxylate transporter 8 for tissue transport. Endocrinology. 2009;150:4450-4458.
21. Verge CF, Konrad D, Cohen M, et al. Diiodothyropropionic acid (DITPA) in the treatment of MCT8 deficiency. J Clin Endocrinol Metab. 2012;97:4515-4523
22. Nakamura Y, Chopra IJ, Solomon DH. An assessment of the concentration of acetic acid and propionic acid derivatives of 3,5,3′-triiodothyronine in human serum. J Clin Endocrinol Metab. 1978;46:91-97. (Pubitemid 8295351)
23. Engler D, Burger AG. The deiodination of the iodothyronines and of their derivatives in man. Endocr Rev. 1984;5:151-184.
24. Wu SY, Green WL, Huang WS, Hays MT, Chopra IJ. Alternate pathways of thyroid hormone metabolism. Thyroid. 2005;15:943-958. (Pubitemid 41339272)
25. Green WL, Ingbar SH. The peripheral metabolism of tri- and tetraiodothyroacetic acids in man. J Clin Endocrinol Metab. 1961;21:1548-1565.
26. Pitt-Rivers R. Physiological activity of the acetic-acid analogues of some iodinated thyronines. Lancet. 1953;265:234-235.
27. Lerman J, Pitt-Rivers R. Physiologic activity of triiodo- and tetraiodothyroacetic acid in human myxedema. J Clin Endocrinol Metab. 1956;16:1470-1479.
28. Lerman J. Dissociation of response to triiodothyroacetic acid in myxedema: comparison with response to thyroid substance. J Clin Endocrinol Metab. 1961;21:1044-1053.
29. Kunitake JM, Hartman N, Henson LC, Lieberman J, Williams DE, Wong M, Hershman JM. 3,5,3′-Triiodothyroacetic acid therapy for thyroid hormone resistance. J Clin Endocrinol Metab. 1989;69:461-466. (Pubitemid 19208480)
30. Ueda S, Takamatsu J, Fukata S, et al. Differences in response of thyrotropin to 3,5,3′-triiodothyronine and 3,5,3′-triiodothyroacetic acid in patients with resistance to thyroid hormone. Thyroid. 1996;6:563-570. (Pubitemid 126618471)
31. Radetti G, Persani L, Molinaro G, et al. Clinical and hormonal outcome after two years of triiodothyroacetic acid treatment in a child with thyroid hormone resistance. Thyroid. 1997;7:775-778. (Pubitemid 28086211)
32. 3 receptor isoform- and response element-specific. Mol Cell Endocrinol. 2000;165:57-66.
33. Menegay C, Juge C, Burger AG. Pharmacokinetics of 3,5,3′- triiodothyroacetic acid and its effects on serum TSH levels. Acta Endocrinol (Copenh). 1989;121:651-658. (Pubitemid 19281004)
34. Liang H, Juge-Aubry CE, O'Connell M, Burger AG. Organ-specific effects of 3,5,3′-triiodothyroacetic acid in rats. Eur J Endocrinol. 1997;137:537-544.
35. Mansouri A, Chowdhury K, Gruss P. Follicular cells of the thyroid gland require Pax8 gene function. Nat Genet. 1998;19:87-90. (Pubitemid 28242031)
36. -/- mutant mice can be rescued by inactivating the TRα gene. Mol Endocrinol. 2002;16:24-32.
37. Trajkovic-Arsic M, Muller J, Darras VM, et al. Impact of monocarboxylate transporter-8 deficiency on the hypothalamus-pituitary-thyroid axis in mice. Endocrinology. 2010;151:5053-5062.
38. Heuer H, Mason CA. Thyroid hormone induces cerebellar Purkinje cell development via the thyroid hormone receptor α1. J Neurosci. 2003;23:10604-10612. (Pubitemid 37485274)
39. -/- mouse model of congenital hypothyroidism. Endocrinology. 2003;144:777-784.
40. Friesema EC, Jansen J, Jachtenberg JW, Visser WE, Kester MH, Visser TJ. Effective cellular uptake and efflux of thyroid hormone by human monocarboxylate transporter 10. Mol Endocrinol. 2008;22:1357-1369. (Pubitemid 351786996)
41. Iniguez MA, De Lecea L, Guadano-Ferraz A, et al. Cell-specific effects of thyroid hormone on RC3/neurogranin expression in rat brain. Endocrinology. 1996;137:1032-1041. (Pubitemid 26070383)
42. Gilbert ME, Sui L, Walker MJ, et al. Thyroid hormone insufficiency during brain development reduces parvalbumin immunoreactivity and inhibitory function in the hippocampus. Endocrinology. 2007;148:92-102. (Pubitemid 46021441)
43. Namba N, Etani Y, Kitaoka T, et al. Clinical phenotype and endocrinological investigations in a patient with a mutation in the MCT8 thyroid hormone transporter. Eur J Pediatr. 2008;167:785-791. (Pubitemid 351733513)
44. 1H magnetic resonance spectroscopy in monocarboxylate transporter 8 gene deficiency. J Clin Endocrinol Metab. 2008;93:1854-1859.
45. Vaurs-Barriere C, Deville M, Sarret C, et al. Pelizaeus-Merzbacher-like disease presentation of MCT8 mutated male subjects. Ann Neurol. 2009;65:114-118.
46. Pacini F, Sridama V, Refetoff S. Multiple complications of propylthiouracil treatment: granulocytopenia, eosinophilia, skin reaction and hepatitis with lymphocyte sensitization. J Endocrinol Invest. 1982;5:403-407. (Pubitemid 13117916)
47. Asteria C, Rajanayagam O, Collingwood TN, et al. Prenatal diagnosis of thyroid hormone resistance. J Clin Endocrinol Metab. 1999;84:405-410. (Pubitemid 29075660)
48. Guran T, Turan S, Bircan R, Bereket A. 9 years follow-up of a patient with pituitary form of resistance to thyroid hormones (PRTH): comparison of two treatment periods of D-thyroxine and triiodothyroacetic acid (TRIAC). J Pediatr Endocrinol Metab. 2009;22:971-978.
49. Mellström B, Naranjo JR, Santos A, Gonzalez M, Bernal J. Independent expression of the α and β c-erbA genes in developing rat brain. Mol Endocrinol. 1991;5:1339-1350.
50. Bradley DJ, Towle HC, Young WS. Spatial and temporal expression of α- and β thyroid hormone receptor mRNAs, including the β2-subtype, in the developing mammalian nervous system. J Neurosci. 1992;12:2288-2302.
51. Wallis K, Dudazy S, van Hogerlinden M, Nordstrom K, Mittag J, Vennstrom B. The thyroid hormone receptor α1 protein is expressed in embryonic postmitotic neurons and persists in most adult neurons. Mol Endocrinol. 2010;24:1904-1916.
52. Gereben B, Salvatore D. Pretranslational regulation of type 2 deiodinase. Thyroid. 2005;15:855-864. (Pubitemid 41339264)
53. Gereben B, Zavacki AM, Ribich S, et al. Cellular and molecular basis of deiodinase-regulated thyroid hormone signaling. Endocr Rev. 2008;29:898-938.
54. Williams GR, Bassett JH. Deiodinases: the balance of thyroid hormone: local control of thyroid hormone action: role of type 2 deiodinase. J Endocrinol. 2011;209:261-272.
55. Lameloise N, Siegrist-Kaiser C, O'Connell M, Burger A. Differences between the effects of thyroxine and tetraiodothyroacetic acid on TSH suppression and cardiac hypertrophy. Eur J Endocrinol. 2001;144:145-154. (Pubitemid 32181685)
56. Hernandez A. Structure and function of the type 3 deiodinase gene. Thyroid. 2005;15:865-874. (Pubitemid 41339265)
57. Dentice M, Salvatore D. Deiodinases: the balance of thyroid hormone: local impact of thyroid hormone inactivation. J Endocrinol. 2011;209:273-282.
58. Dupre SM, Guissouma H, Flamant F, et al. Both thyroid hormone receptor (TR)β1 and TRβ2 isoforms contribute to the regulation of hypothalamic thyrotropin-releasing hormone. Endocrinology. 2004;145:2337-2345. (Pubitemid 38535063)
59. Guissouma H, Froidevaux MS, Hassani Z, Demeneix BA. In vivo siRNA delivery to the mouse hypothalamus confirms distinct roles of TRβ isoforms in regulating TRH transcription. Neurosci Lett. 2006;406:240-243. (Pubitemid 44322024)